Other Events. On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al. , Appeal No. 25-1236, affirming the judgment of the U.S. District Court for the District of Delaware that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. The Court of Appeals also dismissed as moot MSN’s appeal relating to the validity of U.S. Patent…

Results of Operations and Financial Condition. On August 5, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended July 3, 2026, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

The filing is about the approval of an equity incentive plan amendment, not a management change.

Results of Operations and Financial Condition. On May 5, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended April 3, 2026, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or o…

Other Events. Stock Repurchase On May 5, 2026, Exelixis announced that the Board of Directors authorized the repurchase of up to an additional $750 million of its common stock by December 31, 2027. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled “October 2025 Stock Repurchase Program (SRP) Update and Announcement of New $750 million SRP Authorized in May 2026.”

Results of Operations and Financial Condition. On February 10, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended January 2, 2026 and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Results of Operations and Financial Condition. On January 11, 2026, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended January 2, 2026, providing financial guidance for the fiscal year ending January 1, 2027, and delivered an update on its business. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The preliminary unaudited financial results c…

General Counsel — Jeffrey Hessekiel: The Executive Vice President and General Counsel is resigning from the company, representing a genuine departure of a senior officer, though the filing notes no disagreement with the company.

Results of Operations and Financial Condition. On November 4, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended October 3, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…

Other Events. Stock Repurchase On November 4, 2025, Exelixis announced that the Board of Directors authorized the repurchase of up to $750 million of its common stock before December 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled “Stock Repurchase Program.”

Chief Medical Officer — Amy C. Peterson: The filing discloses the departure of the Chief Medical Officer, a senior executive role, without an immediate named successor, which constitutes a genuine loss of key management.

Results of Operations and Financial Condition. On July 28, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended July 4, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition. On May 13, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended April 4, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

The filing discloses a special equity award program for retention and incentive purposes, not a change in management personnel.

Other Events. Stock Repurchase On February 20, 2025, Exelixis, Inc. announced that the Board of Directors authorized the repurchase of up to an additional $500 million of its common stock before December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On February 11, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended January 3, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Results of Operations and Financial Condition. On January 12, 2025, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended January 3, 2025, providing financial guidance for the fiscal year ending January 2, 2026, and delivered an update on its business. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The preliminary unaudited financial results c…

Results of Operations and Financial Condition. On October 29, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended September 27, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Other Events. On October 14, 2024, Exelixis, Inc. (Exelixis) announced that it has entered into a clinical development collaboration (Collaboration) with Merck & Co., Inc., known as MSD outside of the United States and Canada (Merck), to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a phase 3 pivotal trial for the treatment of patients with head and neck squamous cell carcinoma (H…

Other Events. Stock Repurchase On August 6, 2024, Exelixis announced that the Board of Directors authorized the repurchase of up to $500 million of its common stock before the end of 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled “Announcement of Additional Stock Repurchase Program for up to $500 Million through the End of 2025.”

Results of Operations and Financial Condition. On August 6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended June 28, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

The filing describes the approval of an Employee Stock Purchase Plan amendment, which is a compensatory arrangement rather than a change in management or board composition.

Other Events. On May 20, 2024 Exelixis, Inc. (Exelixis) announced that it has entered into a Settlement and License Agreement (the Agreement) with Cipla Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets (20 mg / 40 mg / 60 mg) prior to the expiration of the appli…

Other Events. On March 27, 2024, we received notice from Cipla Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla) that it had amended its Abbreviated New Drug Application (ANDA), originally filed with the U.S. Food and Drug Administration (FDA) more than one year ago, to assert additional Paragraph IV certifications. The ANDA now requests approval to market generic versions of CABOMETYX tablets with 20 mg and 40 mg dosage strengths (in addition to the 60 mg dosage s…

Results of Operations and Financial Condition. On April 30, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended March 29, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…